Major Depressive Disorder (MDD) | Primary Research (KOL's Insight) | Competitive Intelligence

Description

Current treatment of MDD aims to fully resolve the disease-induced symptoms, to improve the quality of life and functionality in daily life. Despite advancements in MDD treatment and management options, improvements have failed to meet patient desired outcomes. Several emerging therapies such as Dextromethorphan+bupropion/AXS-05 (Axsome Therapeutics), Ansofaxine hydrochloride/LY03005 (Luye Pharma), Zuranolone/SAGE-217 (Biogen Inc./Sage Therapeutics/ Shionogi) are coming up to address the current challenges of MDD patients.

Major depressive disorder (MDD), also referred to as clinical depression, is a debilitating disease that is characterized by depressed mood, diminished interests, impaired cognitive function, and vegetative symptoms, such as disturbed sleep or appetite. MDD is associated with alterations in regional brain volumes, particularly the hippocampus, and with functional changes in brain circuits, such as the cognitive control network and the affective-salience network. Furthermore, disturbances in the main neurobiological stress-responsive systems, including the hypothalamic-pituitary-adrenal axis and the immune system, occur in MDD.

MDD is diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5 criteria. The patient must have at least five of the stated symptoms present during the same two-week period. One of the symptoms must include diminished interest/pleasure or depressed mood. In addition to a psychiatric evaluation, diagnosis of MDD could also include physical and/or blood tests to rule out causes for other conditions such as substance abuse, medical conditions such as diabetes and hypothyroidism, as well as other psychiatric disorders.

Major Depressive Disorder (MDD) Prevalence (Epidemiology)

The total prevalent cases in the G7 countries are anticipated to rise to 51,356,131 by 2032 for the study period (2018-2032).

Major depression is one of the most common mental disorders in the United States. According to the 1-year prevalence data published by National Survey on Drug Use and Health (NSDUH), there were approximately 19.4 million adults in the US that had at least one major depressive episode in the year 2019.

As per estimates, the United States accounted for the highest prevalence of Major Depressive Disorder (MDD) cases in 2018 which was 30,756,221 cases, and is expected to experience a significant rise by 2032 with an impressive CAGR for the study period 2018-2032. Among the EU5, the UK had the highest Major Depressive Disorder (MDD) cases, followed by France, Germany, Italy, and Spain. Japan is reported to have the highest number of cases after the United States and the UK.

Major Depressive Disorder (MDD) Current Market Size & Forecast Trends

The Major depressive disorder (MDD) therapeutics market is expected to increase at a significant rate during the forecast period i.e. 2022-2032. In the year 2022, the market is rapidly evolving and developing at a consistent rate and will depend on the strategies and vision of the major market players. The current MDD treatment market includes tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics.

The increasing prevalence of major depressive disorder, the increasing usage of antidepressants and augmentation medications will drive the MDD market. Additionally, the introduction of new therapies such as Spravato, AXS-05, LY03005, Zuranolone, REL-1017, and others will drive the market growth during the forecast period from 2022-to 2032.

Report Highlights:

Major Depressive Disorder (MDD) - Current Market Trends

Major Depressive Disorder (MDD) - Current & Forecasted Cases across the G7 Countries

Major Depressive Disorder (MDD) - Market Opportunities And Sales Potential for Agents

Major Depressive Disorder (MDD) - Patient-based Market Forecast to 2032

Major Depressive Disorder (MDD) - Untapped Business Opportunities

Major Depressive Disorder (MDD) - Product Positioning Vis-a-vis Competitors' Products

Major Depressive Disorder (MDD) - KOLs Insight

Product Code: MM202046

Executive Summary

Key Findings

Major Depressive Disorder (MDD) Disease Background

Major Depressive Disorder (MDD) Definition
Symptoms & Causes
Pathophysiology
Diagnosis
- MDD Assessment Tools
- Additional Details on Selected Depression Scales
- Diagnostic Criteria
Primary Nonresponders Are at Risk of Developing TRD

Epidemiology Estimated and Forecast to 2032

Key Findings
Methods and Data Sources
- Country Specific Prevalent cases of Major Depressive Disorder (MDD) (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Drug Treated Cases of Major Depressive Disorder (MDD)

Key Sources for Major Depressive Disorder (MDD) Epidemiology and Model Parameters

The United States
- The United States Prevalent cases of Major Depressive Disorder (MDD)
- United States Drug Treated Cases of Major Depressive Disorder (MDD)
Germany
- Germany Prevalent cases of Major Depressive Disorder (MDD)
- Germany Drug Treated Cases of Major Depressive Disorder (MDD)
France
- France Prevalent cases of Major Depressive Disorder (MDD)
- France Drug Treated Cases of Major Depressive Disorder (MDD)
Italy
- Italy Prevalent cases of Major Depressive Disorder (MDD)
- Italy Drug Treated Cases of Major Depressive Disorder (MDD)
Spain
- Spain Prevalent cases of Major Depressive Disorder (MDD)
- Spain Drug Treated Cases of Major Depressive Disorder (MDD)
The United Kingdom
- United Kingdom Prevalent cases of Major Depressive Disorder (MDD)
- United Kingdom Drug Treated Cases of Major Depressive Disorder (MDD)
Japan
- Japan Prevalent cases of Major Depressive Disorder (MDD)
- Japan Drug Treated Cases of Major Depressive Disorder (MDD)

Current Therapies and Medical Practice

Treatments & Medical Practices
Potential Treatment Guidelines/Algorithms
Clinical Guidelines for the Treatment of Depression
Dosing of medications shown to be effective In treating Major Depressive Disorder (MDD)
Marketed treatment for Major Depressive Disorder (MDD)
Potential treatments for side effects of antidepressant medications in Major Depressive Disorder (MDD)

Unmet Needs

Marketed Therapies

Esketamine hydrochloride (Johnson & Johnson)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032

Emerging Therapies

Pipeline Overview
Therapeutic Developments Pipeline for Major Depressive Disorder (MDD)
- Product Analysis
AXS-05 (Axsome Therapeutics Inc.)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
LY03005 (Luye Pharma)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
Zuranolone (Biogen Inc./Sage Therapeutics/Shionogi)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
Cariprazine (Gedeon Richter Plc./Abbvie)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
Caplyta (Intra-Cellular Therapies Inc.)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
REL-1017 (Relmada Therapeutics Inc.)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
Seltorexant (Minerva Neurosciences/Janssen/Royalty Pharma)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
PRAX-114 (Praxis Precision Medicines Inc.)
- Product Profile
- Clinical Development
SPL026 (Small Pharma)
- Product Profile
- Clinical Development
SLS-002 (Seelos Therapeutics Inc.)
- Product Profile
- Clinical Development
Psilocybin (Usona Institute/The Emmes Company/Signant Health)
- Product Profile
- Clinical Development
PH10 (Pherin Pharmaceuticals/VistaGen Therapeutics)
- Product Profile
AV-101 (VistaGen Therapeutics Inc.)
- Product Profile
- Clinical Development
Other Emerging Drugs For Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)- Reimbursement Scenario

Major Depressive Disorder (MDD)- Cost Burden & Prescriptions survey

Future Treatment Paradigm

Major Depressive Disorder (MDD) Competitor Landscape and Approvals Anticipated
Future Treatment Algorithms and Competitor Positioning
Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

Key Findings
Country-Specific Market Forecast to 2032
- G7 total Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- G7 total Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)

Market Forecast by Country

The United States
- United States Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- United States Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
Germany
- Germany Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- Germany Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
France
- France Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- France Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
Italy
- Italy Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- Italy Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
Spain
- Spain Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- Spain Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
The United Kingdom
- United Kingdom Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- United Kingdom Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)
Japan
- Japan Market for Major Depressive Disorder (MDD) 2018-2032 (USD Million)
- Japan Market for Major Depressive Disorder (MDD) by Therapies 2018-2032 (USD Million)

Market Drivers and Constraints

What Factors Are Driving the Market for Major Depressive Disorder (MDD)?
What Factors Are Constraining the Market for Major Depressive Disorder (MDD)?

Appendix

About Mellalta Meets

Major Depressive Disorder (MDD) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2032